Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 9
Outcomes with Faricimab and Choosing Between the New Therapies
Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.
Video content above is prompted by the following:
- In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Recent Videos
Related Content
